Recurrent Metastatic Head And Neck Squamous Cell Carcinoma clinical trials

Explore recruiting recurrent metastatic head and neck squamous cell carcinoma clinical trials.

Recruiting recurrent metastatic head and neck squamous cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Recurrent Metastatic Head And Neck Squamous Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Multicenter, Randomized Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)

Norway, Denmark, Portugal, Romania, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Portugal, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Italy, Portugal, Spain, Romania, Hungary, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Spain, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Recurrent Metastatic Head And Neck Squamous Cell Carcinoma trials by city

Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Toronto Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Vancouver Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Montreal Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Calgary Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Edmonton Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Ottawa Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Winnipeg Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Quebec City Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Hamilton Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Kitchener Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in London Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Halifax Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in New York Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Los Angeles Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Chicago Recurrent Metastatic Head And Neck Squamous Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease